First test for stem-cell institute -- money
By Jesse Reynolds,
San Francisco Chronicle
| 05. 15. 2005
Funding mechanism must avoid conflict of interest
The authors of last November's successful Proposition 71, the stem- cell research initiative, asked California voters to trust them in two distinct ways.
First, they convinced voters -- in some cases with shamelessly exaggerated promises about the imminence and likelihood of cures -- to invest $3 billion in research that has potential but is still at an early stage.
The second request was written into the initiative in print so fine that few voters had a chance of understanding it. Using obscure legalese, the initiative exempted the state agency it created, the California Institute for Regenerative Medicine, from many of the hard-won legal protections meant to ensure effective and transparent state governance. The result is that the institute, an agency entirely funded by the California public, is being run according to the practices of private enterprise. It best resembles a publicly funded, privately managed venture capital firm.
Now this experiment is facing a major obstacle. Lawsuits are challenging the constitutionality of Prop. 71's exclusion of public and legislative oversight. The state attorney general has determined that the bonds to fund...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...